Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension

Hypertension Research

Volumn 30, Issue 4, 2007, Pages 307-313

  Miyajima, Katsuaki ^a   Minatoguchi, Shinya ^a   Ito, Yoko ^a   Hukunishi, Masanori ^a   Matsuno, Yasunari ^a   Kakami, Masao ^a   Kawasaki, Masanori ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Oxidative stress; QT dispersion; Valsartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; LIPID PEROXIDASE; PROCOLLAGEN; PROCOLLAGEN TYPE 1; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; MALE; MONOTHERAPY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; QT DISPERSION; QT INTERVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS BLOOD;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLAGEN TYPE I; COLLAGEN TYPE III; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPID PEROXIDATION; LONG QT SYNDROME; MALE; OXIDATIVE STRESS; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 34249080316     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.307     Document Type: Article

References (29)

1. Levy D, Garrison RJ, Savage DD, Kannel EB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Kannel WB: Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991; 9 (2): S3-S9.
3. Messerli FH, Schmieder R: Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31 (Suppl 4): 192-201.
4. Frohlich ED: Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertension 2001; 14: 194S-199S.
5. van de Loo A, Arendts W, Hohnloser SH: Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol 1994; 74: 1113-1118.
6. Zabel M, Portnoy S, Franz MR: Electrocardiographic indexes of dipersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 1995; 25: 746-754.
7. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD: QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327-329.
8. Zareba W, Moss AJ, Lecessie S: Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994; 74: 550-553.
9. de Bruyne MC, Hoes AW, Kors JA, Hofman A, Van Bemmel JH, Grobbee DE: QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97: 467-472.
10. Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G: QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Heart 1994; 71: 268-273.
11. Clarkson PBM, Naas AAO, McMahon A, MacLeod C, Hart G: QT interval dispersion in essential hypertension. QJM 1995; 88: 327-332.
12. Matsumura K, Takata Y, Ansai T, et al: Association of QT interval with blood pressure in 80-year-old subjects. Hypertens Res 2004; 27: 387-391.
13. Grozier IG, Richards AM, Ikram H, Nicholls MG: The renin-angiotensin system, ACE inhibitors, and cardiac structure, in Robertson JIS (ed): Tbe Renin-Angiotensin System. New York, Gower Medical Publishing, 1993, pp 1-94.
14. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
15. Bednarz B, Chamiec T, Ceremuzynski L: Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction. Kardiol Pol 2003; 58: 375-379.
16. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 7: 450-458.
17. Dahlof B, Pennart K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
18. Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF: Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes 2006; 7: 51-59.
19. Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K: Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005; 69: 1244-1248.
20. Poulsen SH, Andersen NH, Heickendorff L, Mogensen CE: Relation between plasma amino-terminal propeptide of pro-collagen type III and left ventricular longitudinal strain in essential hypertension. Heart 2005; 91: 624-629.
21. Jeron A, Hengstenberg C, Engel S, et al: The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J 2001; 22: 618-621.
22. Gonzalez-Juanatey JR, Garcia-Acuna JM, Pose A, et al: Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol 1998; 81: 170-174.
23. Ranade V, Molnar J, Khokher T, Agarwal A, Mosnaim A, Somberg JC: Effect of angiotensn-converting enzyme therapy on QT interval dispersion. Am J Ther 1999; 6: 257-261.
24. Lim PO, Nys M, Naas AAO, Struthers AD, Osbakken M, MacDonald TM: Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33: 713-718.
25. Malmqvist K, Kahan T, Edner M, Bergfeldt L: Comparison of action of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Am J Cardiol 2002; 90: 1107-1112.
26. Crozier IG, Richards AM, Ikram H, Nicholls MG: The renin-angiotensin system, ACE inhibitors, and cardiac structure, in Robertson JIS (ed): The Renin-Angiotensin System. New York, Gower Medical Publishing, 1993, pp 1-94.
27. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
28. Karpanou EA, Vyssoulis GP, Psichogios A, et al: Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136: 765-768.
29. Ohta M, Nanri H, Matsushima Y, Sato Y, Ikeda M: Blood pressure-lowering effects of lifestyle modification: possible involvement of nitric oxide bioavailability. Hypertens Res 2005; 28: 779-786.